---
id: "action-portfolio-management"
type: "action-item"
source_timestamps: ["§ 1. Embrace a new model for accelerating drug development."]
tags: ["management", "r-and-d"]
related: ["concept-in-house-accelerators", "entity-stanford-ima"]
action: "Adopt industry-style portfolio management to actively prioritize and expedite first-in-class therapeutic candidates internally."
outcome: "Faster transition of early-stage discoveries into active clinical development pipelines."
speakers: ["Anaeze C. Offodile II", "Kushal T. Kadakia", "Yashodhara Dash", "Whitney Snider", "Joseph C. Wu", "Selwyn M. Vickers"]
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# Implement Industry-Style Portfolio Management

**Action:** Transition from passive technology transfer ([[prereq-tech-transfer]]) to **active, industry-style portfolio management** within the AMC — explicitly prioritizing research with **first-in-class potential** and matching it with external partners.

**Mechanism:** the in-house-accelerator model of [[concept-in-house-accelerators]], exemplified by [[entity-stanford-ima]] (Pillar 1 of [[framework-amc-innovation-acceleration]]).

**Outcome:** faster transition of early-stage discoveries into active clinical-development pipelines.